Clinical Effectiveness and Safety of Vericiguat in Worsening Heart Failure with Reduced Ejection Fraction: A Single-center, Retrospective Analysis in Indian Patients

Background and Objective: In a tertiary care hospital in India, investigators evaluated the efficacy and safety of vericiguat, a new oral soluble guanylate cyclase stimulator in patients with worsening symptoms of heart failure and reduced ejection fraction (HFrEF). Methods: A retrospective assessme...

Full description

Saved in:
Bibliographic Details
Main Authors: Pankaj Jariwala, Avvaru Guru Prakash, Poondru Rohith Reddy, Dilip Gude, Gururaj Pramod Kulkarni, Arshad Punjani, Harikishan Boorugu, Dilip Babu Madhawar, Anusha Jariwala
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2025-01-01
Series:Journal of the Practice of Cardiovascular Sciences
Subjects:
Online Access:https://journals.lww.com/10.4103/jpcs.jpcs_63_24
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849323923301203968
author Pankaj Jariwala
Avvaru Guru Prakash
Poondru Rohith Reddy
Dilip Gude
Gururaj Pramod Kulkarni
Arshad Punjani
Harikishan Boorugu
Dilip Babu Madhawar
Anusha Jariwala
author_facet Pankaj Jariwala
Avvaru Guru Prakash
Poondru Rohith Reddy
Dilip Gude
Gururaj Pramod Kulkarni
Arshad Punjani
Harikishan Boorugu
Dilip Babu Madhawar
Anusha Jariwala
author_sort Pankaj Jariwala
collection DOAJ
description Background and Objective: In a tertiary care hospital in India, investigators evaluated the efficacy and safety of vericiguat, a new oral soluble guanylate cyclase stimulator in patients with worsening symptoms of heart failure and reduced ejection fraction (HFrEF). Methods: A retrospective assessment was conducted on patients with HFrEF and deteriorating symptoms who received either guideline-directed medical therapy (GDMT) or vericiguat, in addition to GDMT. The main result was a combination of death and hospitalization for heart failure (HF). Other measured results included systolic and diastolic blood pressure (DBP), left ventricular ejection fraction (LVEF), levels of N-terminal probrain natriuretic peptide (NT-pro BNP), kidney function, and sodium and potassium levels in the body. Results: After 6 months, 11 patients in the vericiguat group (22%) and 25 patients in the GDMT group (50%) experienced a primary composite event of death or hospitalization for HF. The administration of vericiguat resulted in a notable enhancement of the clinical indicators of HF, such as LVEF and NT-proBNP levels (P < 0.001). Administration of vericiguat at a dosage of 10 mg once a day, in conjunction with GDMT, did not have any negative effects on systolic or DBP, renal function, or electrolyte balance compared to GDMT alone. Conclusion: In patients experiencing deteriorating HF, the administration of vericiguat resulted in a notable decrease in cardiovascular mortality or hospitalization for HF compared with those who only received GDMT. This study emphasizes the efficacy and safety of vericiguat therapy in Indian patients with deteriorating HF.
format Article
id doaj-art-c7798a7441c347e99b514b3ccbe4315e
institution Kabale University
issn 2395-5414
2454-2830
language English
publishDate 2025-01-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Journal of the Practice of Cardiovascular Sciences
spelling doaj-art-c7798a7441c347e99b514b3ccbe4315e2025-08-20T03:48:52ZengWolters Kluwer Medknow PublicationsJournal of the Practice of Cardiovascular Sciences2395-54142454-28302025-01-01111626910.4103/jpcs.jpcs_63_24Clinical Effectiveness and Safety of Vericiguat in Worsening Heart Failure with Reduced Ejection Fraction: A Single-center, Retrospective Analysis in Indian PatientsPankaj JariwalaAvvaru Guru PrakashPoondru Rohith ReddyDilip GudeGururaj Pramod KulkarniArshad PunjaniHarikishan BooruguDilip Babu MadhawarAnusha JariwalaBackground and Objective: In a tertiary care hospital in India, investigators evaluated the efficacy and safety of vericiguat, a new oral soluble guanylate cyclase stimulator in patients with worsening symptoms of heart failure and reduced ejection fraction (HFrEF). Methods: A retrospective assessment was conducted on patients with HFrEF and deteriorating symptoms who received either guideline-directed medical therapy (GDMT) or vericiguat, in addition to GDMT. The main result was a combination of death and hospitalization for heart failure (HF). Other measured results included systolic and diastolic blood pressure (DBP), left ventricular ejection fraction (LVEF), levels of N-terminal probrain natriuretic peptide (NT-pro BNP), kidney function, and sodium and potassium levels in the body. Results: After 6 months, 11 patients in the vericiguat group (22%) and 25 patients in the GDMT group (50%) experienced a primary composite event of death or hospitalization for HF. The administration of vericiguat resulted in a notable enhancement of the clinical indicators of HF, such as LVEF and NT-proBNP levels (P < 0.001). Administration of vericiguat at a dosage of 10 mg once a day, in conjunction with GDMT, did not have any negative effects on systolic or DBP, renal function, or electrolyte balance compared to GDMT alone. Conclusion: In patients experiencing deteriorating HF, the administration of vericiguat resulted in a notable decrease in cardiovascular mortality or hospitalization for HF compared with those who only received GDMT. This study emphasizes the efficacy and safety of vericiguat therapy in Indian patients with deteriorating HF.https://journals.lww.com/10.4103/jpcs.jpcs_63_24cardiovascular mortalityhospitalization for heart failuresoluble guanylyl cyclasevericiguatworsening heart failure
spellingShingle Pankaj Jariwala
Avvaru Guru Prakash
Poondru Rohith Reddy
Dilip Gude
Gururaj Pramod Kulkarni
Arshad Punjani
Harikishan Boorugu
Dilip Babu Madhawar
Anusha Jariwala
Clinical Effectiveness and Safety of Vericiguat in Worsening Heart Failure with Reduced Ejection Fraction: A Single-center, Retrospective Analysis in Indian Patients
Journal of the Practice of Cardiovascular Sciences
cardiovascular mortality
hospitalization for heart failure
soluble guanylyl cyclase
vericiguat
worsening heart failure
title Clinical Effectiveness and Safety of Vericiguat in Worsening Heart Failure with Reduced Ejection Fraction: A Single-center, Retrospective Analysis in Indian Patients
title_full Clinical Effectiveness and Safety of Vericiguat in Worsening Heart Failure with Reduced Ejection Fraction: A Single-center, Retrospective Analysis in Indian Patients
title_fullStr Clinical Effectiveness and Safety of Vericiguat in Worsening Heart Failure with Reduced Ejection Fraction: A Single-center, Retrospective Analysis in Indian Patients
title_full_unstemmed Clinical Effectiveness and Safety of Vericiguat in Worsening Heart Failure with Reduced Ejection Fraction: A Single-center, Retrospective Analysis in Indian Patients
title_short Clinical Effectiveness and Safety of Vericiguat in Worsening Heart Failure with Reduced Ejection Fraction: A Single-center, Retrospective Analysis in Indian Patients
title_sort clinical effectiveness and safety of vericiguat in worsening heart failure with reduced ejection fraction a single center retrospective analysis in indian patients
topic cardiovascular mortality
hospitalization for heart failure
soluble guanylyl cyclase
vericiguat
worsening heart failure
url https://journals.lww.com/10.4103/jpcs.jpcs_63_24
work_keys_str_mv AT pankajjariwala clinicaleffectivenessandsafetyofvericiguatinworseningheartfailurewithreducedejectionfractionasinglecenterretrospectiveanalysisinindianpatients
AT avvaruguruprakash clinicaleffectivenessandsafetyofvericiguatinworseningheartfailurewithreducedejectionfractionasinglecenterretrospectiveanalysisinindianpatients
AT poondrurohithreddy clinicaleffectivenessandsafetyofvericiguatinworseningheartfailurewithreducedejectionfractionasinglecenterretrospectiveanalysisinindianpatients
AT dilipgude clinicaleffectivenessandsafetyofvericiguatinworseningheartfailurewithreducedejectionfractionasinglecenterretrospectiveanalysisinindianpatients
AT gururajpramodkulkarni clinicaleffectivenessandsafetyofvericiguatinworseningheartfailurewithreducedejectionfractionasinglecenterretrospectiveanalysisinindianpatients
AT arshadpunjani clinicaleffectivenessandsafetyofvericiguatinworseningheartfailurewithreducedejectionfractionasinglecenterretrospectiveanalysisinindianpatients
AT harikishanboorugu clinicaleffectivenessandsafetyofvericiguatinworseningheartfailurewithreducedejectionfractionasinglecenterretrospectiveanalysisinindianpatients
AT dilipbabumadhawar clinicaleffectivenessandsafetyofvericiguatinworseningheartfailurewithreducedejectionfractionasinglecenterretrospectiveanalysisinindianpatients
AT anushajariwala clinicaleffectivenessandsafetyofvericiguatinworseningheartfailurewithreducedejectionfractionasinglecenterretrospectiveanalysisinindianpatients